Biologic therapies targeting TNF-α and IL-6 in rheumatoid arthritis may provide dual benefits, improving both joint-related disease activity and neuropsychiatric symptoms such as depression, fatigue, and cognitive dysfunction. This evidence concerns the gene TNF and rheumatoid arthritis.